News & explainers
What changed in peptide research and regulation, and what it means, without the hype.
October 7, 2026 · 4 min read
Retatrutide's phase 3 TRIUMPH results: what they showed and what comes next
Four phase 3 trials of Eli Lilly's triple-hormone drug reported strong weight loss in 2025–2026. Here is what the numbers mean, the new side effect to know about, and the filing timeline.
October 6, 2026
How to read a peptide certificate of analysis
A COA is the lab report behind a vial. Here is what purity, identity, peptide content, endotoxin and sterility results mean, and the red flags to watch for.
October 2, 2026
Growth hormone secretagogues compared: ipamorelin, CJC-1295, tesamorelin and sermorelin
Four peptides that prompt the body to release its own growth hormone. How they work, how strong the evidence is, which were ever approved, and where WADA stands.
October 1, 2026
FDA's 2026 peptide compounding changes, explained
In April the FDA took 12 peptides off its compounding safety-concern list, and in July an advisory panel voted on seven. Here is what each step means, and what it doesn't.
September 29, 2026
Semax and Selank explained: Russia's nasal peptides
Semax and Selank are registered medicines in Russia and unapproved almost everywhere else. Here is what the research shows, and what is known about Adamax and Adalank.
September 27, 2026
Compounded GLP-1s after the shortage: where things stand in 2026
The FDA declared the semaglutide and tirzepatide shortages over in 2025. Here is what that changed for compounded versions, what the FDA is policing now, and why 'research' vials are another matter.
September 25, 2026
GHK-Cu and copper peptides: what the skin and hair evidence shows
Copper peptides are in serums everywhere. Here is what has been shown in people, what is still lab work, and why topical and injected use are very different questions.
September 24, 2026
BPC-157 in 2026: what the evidence actually shows
BPC-157 has well over a hundred animal studies and only a handful of tiny human reports behind it. Here is what is known, what is not, and where it stands with the FDA and WADA.
September 22, 2026
CagriSema and amylin: what's next after GLP-1s
CagriSema pairs semaglutide with an amylin analog. Here is what the REDEFINE trials found, where the FDA review stands, and how amylin differs from GLP-1.
September 20, 2026
The most-researched peptides of 2026, ranked by evidence
Twelve peptides people ask about most, sorted by how much human evidence stands behind them, from approved drugs down to compounds with almost no human data.
Get new posts by email
Plus price drops and FDA or WADA changes for the peptides you care about.